Investing.com -- Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg ...

Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...

In recent years, men’s health has shifted from being a quiet, private matter to an open conversation fueled by technology and ...

The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers regarding its advertising and ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

After Bloomberg reported, citing people familiar with the probe, that the Federal Trade Commission has been investigating ...

For more than a year, the Federal Trade Commission has been investigating Hims & Hers Health Inc.’s business practices, including whether it has made it too hard for customers to cancel subscriptions, ...

Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.

Shares of Hims & Hers Health Inc. have roughly doubled over the past year — and Chief Executive Andrew Dudum cashed in on the ...